SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the company...